BarlamT. F.GuptaK., “Antibiotic Resistance Spreads Across Borders,”Journal of Law, Medicine & Ethics43, no. 2, Supp. (2015).
2.
BalasegaramM.CliftC.RøttingenJ.-A., “A Pathway towards an Alternative Business Model for Antibiotic Innovation: A Framework, Fund and Institutional Mechanism,”Journal of Law, Medicine & Ethics43, no. 2, Supp. (2015): Available via aslme.org.
3.
GrabowskiH.MortimerG. L. R., “Recent Trends in Brand-Name and Generic Drug Competition,”Journal of Medical Economics17, no. 3 (2013): 207–214.
4.
DaulaireN.BangA.TomsonG.KalyangoJ. N.CarsO., “Universal Access to Effective Antimicrobials: An Essential Feature of Global Collective Action against Antimicrobial Resistance,”Journal of Law, Medicine & Ethics43, no. 2, Supp. (2015): Available via aslme.org.
5.
CoaseR. H., “The Problem of Social Cost,”Journal of Law and Economics3, no. 1 (1960): 1–44.
6.
A five-year extension has already been implemented in the U.S. under Title VIII of the 2012 Food and Drug Administration Safety and Innovation Act. For a proposed indefinite exclusivity extension, see KadesE., “Preserving a Precious Resource: Rationalizing the Use of Antibiotics,”Northwestern University Law Review99, no. 2 (2005): 611–674. Kades' proposal is effectively rebutted in OuttersonM. K., “The Vanishing Public Domain: Antibiotic Resistance, Pharmaceutical Innovation and Global Public Health,”University of Pittsburgh Law Review67, no. 1 (2005): 67–123.
7.
See HollisA.AhmedZ., “Preserving Antibiotics, Rationally,”New England Journal of Medicine369, no. 26 (2013): 2474–2476, and SoA. D.ShahT. A.RoachS.CheeY. L.NachmanK. E., “International Agreement to Address the Contribution of Animal Agriculture to Antibiotic Resistance: A One Health Approach,”Journal of Law, Medicine & Ethics43, no. 2, Supp. (2015): Available via aslme.org.
8.
For examples of potential policies, see: BehdinanA.HoffmanS. J.PearceyM., “Some Global Policies for Antibiotic Resistance Depend on Legally Binding and Enforceable Commitments,”Journal of Law, Medicine & Ethics43, no. 2, Supp. (2015): Available via aslme.org.
NgaD., “Antibiotic Sales in Rural and Urban Pharmacies in Northern Vietnam: An Observational Study,”BMC Pharmacology and Toxicology15, no. 6 (2014), available at <http://www.biomedcentral.com/2050–6511/15/6> (last visited May 15, 2015).
11.
See Balasaegaram, supra note 3; OuttersonK.PowersJ. H.DanielG. W.McClellanM. B., “Repairing the Broken Market for Antibiotic Innovation,”Health Affairs, 34, no. 2 (2015): 277–285; and points 30 and 31 of the Antibiotic Resistance Coalition – Civil Society Declaration on Antibiotic Resistance, available at <http://www.reactgroup.org/uploads/ARC-declaration/ARC-declaration-May-22-2014.pdf> (last visited May 7, 2015).
12.
See OuttersonK., “New Business Models for Sustainable Antibiotics,”Centre on Global health Security Working Group Papers, Chatham House (The Royal Institute of International Affairs), Working Groups on Antimicrobial Resistance, Paper 1 (2014): 14–10; OuttersonK.PoggeT.HollisA.“Combating Antibiotic Resistance through the Health Impact Fund,” in CohenI. G., ed., The Globalization of Health Care (New York/Oxford: Oxford University Press, 2013); and WHO, Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination, Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (2012), available at <http://www.who.int/phi/cewg_report/en/> (last visited May 13, 2015).